Veloxis Pharmaceuticals AS (VELO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012275
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops therapies for kidney transplantation based on its proprietary MeltDose platform. MeltDose is a drug delivery technology, used to enhance oral bioavailability and control release of a drug. The company’s product portfolio consists of Envarsus XR, anti-rejection drug for patients who had kidney transplantation; and Fenoglide for the treatment of dyslipidemia. The company out licensed the commercial rights of Fenoglide for the US, Canada and Mexico; and Envarsus to Chiesi in Europe, Turkey and CIS countries. It has a wholly owned subsidiary, Veloxis Pharmaceuticals Inc., in New Jersey, the US. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS (VELO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 10
Veloxis Pharma Enters Into Co-Development Agreement With Athena Drug Delivery Solutions 12
Licensing Agreements 13
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Equity Offering 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 18
Veloxis Pharmaceuticals A/S – Key Competitors 19
Veloxis Pharmaceuticals A/S – Key Employees 20
Veloxis Pharmaceuticals A/S – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017 22
Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 23
May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 24
Feb 28, 2017: Veloxis Pharmaceuticals Releases Annual Report for 2016 25
Nov 16, 2016: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2016 26
Aug 24, 2016: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides Corporate Update 27
May 18, 2016: Veloxis Pharmaceuticals announces financial results for the first three months of 2016 28
Mar 09, 2016: Veloxis Pharmaceuticals publishes Annual Report 2015 31
Corporate Communications 32
Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals 32
Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer 33
Jul 26, 2016: Veloxis Pharmaceuticals Passing of Extraordinary General Meeting 34
Apr 06, 2016: Veloxis announces change in management 35
Feb 29, 2016: Veloxis appoints Alastair McEwan as new Chief Operating Officer 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Veloxis Pharmaceuticals A/S, Deals By Therapy Area, 2011 to YTD 2017 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 10
Veloxis Pharma Enters Into Co-Development Agreement With Athena Drug Delivery Solutions 12
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 18
Veloxis Pharmaceuticals A/S, Key Competitors 19
Veloxis Pharmaceuticals A/S, Key Employees 20
Veloxis Pharmaceuticals A/S, Subsidiaries 21

★海外企業調査レポート[Veloxis Pharmaceuticals AS (VELO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Intezyne Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-spec …
  • Visser & Smit Hanab BV:企業の戦略的SWOT分析
    Visser & Smit Hanab BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Summer Infant, Inc.:企業の戦略・SWOT・財務情報
    Summer Infant, Inc. - Strategy, SWOT and Corporate Finance Report Summary Summer Infant, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Micell Technologies Inc:企業の製品パイプライン分析2018
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company provides product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to opt …
  • ASIT Biotech SA (ASIT):製薬・医療:M&Aディール及び事業提携情報
    Summary ASIT Biotech SA (ASIT Biotech), formerly BioTech Tools SA is a clinical stage biopharmaceutical company that develops in-vitro and in-vivo biotech tools. The company develops and commercializes immunotherapy medicines for respiratory and food allergies using ASIT plus technology platform. It …
  • Alliance Pharma Plc (APH):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliance Pharma Plc (Alliance) is a specialty pharmaceutical company. It focuses on acquisition, licensing, registration and marketing of pharmaceutical products. It promotes acquired and licensed prescription products across various therapeutic categories such as dermatology, central nervou …
  • Neste Corporation (NESTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Neste Corp (Neste) is an oil refining and marketing company that offers advanced, clean traffic fuels besides shipping and engineering services. The company produces and sells gasoline; diesel fuel; aviation fuel; bunker fuel; heating oil; light and heavy fuel oil; base oils; gasoline compon …
  • Centrica Plc (CNA):企業の財務・戦略的SWOT分析
    Centrica Plc (CNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Olam International Ltd:企業のM&A・事業提携・投資動向
    Olam International Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Olam International Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • S2Medical AB:製品パイプライン分析
    Summary S2Medical AB (S2Medical) is a medical technology company that designs, develops and markets wound dressings and products to treat burns and chronic ulcers. The company’s product portfolio consists of wound dressing patches; blood stilling synthetic epithelium dressing to control capillary bl …
  • The Timken Co (TKR):企業の財務・戦略的SWOT分析
    The Timken Co (TKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • James Fisher and Sons Plc (FSJ):石油・ガス:M&Aディール及び事業提携情報
    Summary James Fisher and Sons Plc (James Fisher) is a service provider for global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and handling; mar …
  • Ygm Trading Ltd.
    Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ework Group AB (EWRK):企業の財務・戦略的SWOT分析
    Ework Group AB (EWRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Aviation Industry Corporation of China:企業の戦略・SWOT・財務情報
    Aviation Industry Corporation of China - Strategy, SWOT and Corporate Finance Report Summary Aviation Industry Corporation of China - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Canon Medical Systems Corp:企業の戦略的SWOT分析
    Canon Medical Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International) formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, N …
  • Tecpetrol S.A.:企業の戦略・SWOT・財務情報
    Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report Summary Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • CEL-SCI Corp (CVM)-製薬・医療分野:企業M&A・提携分析
    Summary CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biologi …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆